文章核心观点 公司于2025年7月31日发布2025年上半年合并财务报表 ，并公布后续财务日程安排 [1][6] 财务报告 - 报告包含2025年半年管理报告、2025年6月30日合并财务报表以及法定审计师对半年财务信息的审核报告 [2] 公司概况 - 专注于重塑活性成分解决方案 ，是活性药物成分领域领先企业 ，产品组合约有200种产品 [3] - 拥有3270名员工 ，凭借强大研发能力和位于欧洲的5个生产基地 ，为80多个国家的客户提供高质量API制造服务 [4] - 在泛欧证券交易所巴黎上市 ，ISIN为FR0014008VX5 ，股票代码为EAPI [4] 财务日程 - 2026年3月3日公布2025财年业绩 [6] - 2026年5月27日召开2026年年度股东大会 [6] - 2026年7月28日公布2026年上半年业绩 [6] 联系方式 - 媒体关系联系人Laurence Bollack ，电话+33 (0)6 81 86 80 19 ，邮箱mr@euroapi.com [5] - 投资者关系联系人Sophie Palliez - Capian ，电话+33 (0)6 87 89 33 51 ，邮箱sophie.palliez@euroapi.com [5] - 投资者关系联系人Léa Massonneau ，电话+33 (0)7 60 32 29 50 ，邮箱lea.massonneau@euroapi.com [5]

Key Takeaways BHC posted Q2 EPS of $0.90, missing estimates, while revenues rose 5% to $2.53B, beating forecasts.Salix revenues grew 12% to $627M, driven by higher demand for Xifaxan, Trulance, and Relistor.BHC is set to acquire DRRX for $63M, along with milestone payments. Shares of Bausch Health Companies Inc. ((BHC) declined 6.3% after the company reported mixed results for the second quarter of 2025.Adjusted earnings per share of 90 cents missed the Zacks Consensus Estimate of 97 cents. The earnings wer ...

Key Takeaways BIIB's Q2 EPS of $5.47 and revenues of $2.65B beat estimates, driven by new drugs.Vumerity, Leqembi, and Zurzuvae showed strong demand and sequential sales growth in the quarter.BIIB raised its 2025 EPS outlook to $15.50-$16.00 and now sees flat full-year revenue versus prior decline.Biogen (BIIB) reported second-quarter 2025 adjusted earnings per share (EPS) of $5.47, which significantly beat the Zacks Consensus Estimate of $3.93. Earnings rose 4% year over year on a reported basis.Total reve ...

市场表现 - 道指上涨115点 标普500上涨60点 纳斯达克强劲上涨320点 罗素2000小盘股指数下跌0.5% [1] - 债券收益率小幅上升 市场对早间经济数据作出反应 [1] 经济数据 - 6月PCE数据普遍高于预期 与美联储主席前日评论相呼应 [2] - 个人收入环比增长0.3% 超预期10个基点 较5月-0.4%显著反弹 [3] - 个人支出环比增长0.3% 较预期低10个基点 前值上修至0%显示消费谨慎 [3] - 整体PCE环比+0.3%符合预期 核心PCE环比+0.3%持平 [4] - 同比PCE达2.6%创年内新高 核心PCE同比2.8%持平前值 通胀水平高于美联储2%目标 [5][6] 就业市场 - 初请失业金人数7周来首次上升至21.8万 仍远低于6月初25万水平 [7] - 持续申领失业金人数持平于194.6万 此前连续5周下降 [8] - 市场预期7月非农新增就业10万 较前月减少4.7万 [9] 企业财报 - 艾伯维Q2每股收益2.97美元超预期 股价盘前涨4% [10] - CVS健康每股收益1.81美元超预期23% 股价盘前涨8% [10] - 万事达每股收益4.15美元超预期0.1美元 股价盘前涨1% [10] - 百时美施贵宝每股收益1.46美元超预期36% 盘前涨3% [11] - 国际纸业每股收益0.2美元大幅低于预期 盘前跌6.8% [11] - Sirius XM每股收益0.57美元低于预期28% 股价持平 [12] 市场展望 - 芝加哥PMI数据将于开盘后公布 重点关注苹果亚马逊等科技巨头盘后财报 [13] - 苹果预计季度增长温和 亚马逊预计营收利润均实现高个位数增长 [14]

Key Takeaways IONS posted Q2 EPS of $0.86 and revenue of $452M, both beating estimates and doubling year over year.Tryngolza and Wainua drove a 43% rise in commercial revenues, reaching $103M for the quarter.IONS raised its 2025 revenue outlook to $825-$850M, citing strong Tryngolza uptake and market expansion plans.Ionis Pharmaceuticals (IONS) reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, significantly beating the Zacks Consensus Estimate of 27 cents. In the year-ago period, t ...

AbbVie (ABBV) Q2 2025 Earnings Call July 31, 2025 09:00 AM ET Company ParticipantsLiz Shea - Head, IRRobert Michael - CEO & Chairman of BoardJeffrey Stewart - EVP & Chief Commercial OfficerRoopal Thakkar - EVP - R&D & Chief Scientific OfficerScott Reents - EVP & CFOMohit Bansal - Managing DirectorChris Schott - Managing DirectorDavid Risinger - Senior Managing Director, BiopharmaTrung Huynh - Executive Director & Equity ResearchConference Call ParticipantsTerence Flynn - Equity Research AnalystCarter Gould ...

AbbVie (ABBV) Q2 2025 Earnings Call July 31, 2025 09:00 AM ET Speaker0Good morning and thank you for standing by. Welcome to AbbVie's Second Quarter twenty twenty five Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. Today's call is also being recorded. If you have any objections, you may disconnect at this time.I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations. Ma'am, you may begin.Speaker1Thank yo ...

Aurinia Pharmaceuticals (AUPH) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Greetings, and welcome to the Aurinia Pharmaceuticals Second Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Joe Miller, Chief Financial Officer for Aurinia.Thank you. You may begin.Speaker1Thank y ...

Baxter International (BAX) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to Baxter International Second Quarter twenty twenty five Earnings Call. Your lines will remain in a listen only mode until the question and answer segment of today's call. Star one on your touch tone phone. Once again, star and the number one. And as a reminder, this call is being recorded by Baxter and is copyrighted material.It cannot be recorded or rebroadcast without Baxter ...

Agios Pharmaceuticals (AGIO) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Company ParticipantsMorgan Sanford - VP - IRBrian Goff - CEO & DirectorCecilia Jones - CFOTsveta Milanova - Chief Commercial OfficerSarah Gheuens - Chief Medical Officer and Head of Research & DevelopmentImogen Mansfield - VP - Biotech Equity ResearchSalveen Richter - Biotechnology Equity ResearchAndrew Berens - Senior MD - Targeted OncologyTheresa Robb - Director & Head, Global Client Experience Centre Regulatory Governance & Inte ...